Arbutus Biopharma Corporation

Arbutus Biopharma Set to Announce 2023 Year-End Financial Results, Offering Insight into Hepatitis B Cure Progress

WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company known for its work in virology, has revealed it will present its fourth quarter and year-end 2023 financial …

Arbutus Biopharma Set to Announce 2023 Year-End Financial Results, Offering Insight into Hepatitis B Cure Progress Read More